Stock market today: S&P 500 falls as government shutdown, trade jitters persist
Stephen A. Trowbridge, Executive Vice President and CFO of AngioDynamics INC (NASDAQ:ANGO), recently purchased 890 shares of the company’s common stock. The transaction, which occurred on October 13, 2025, involved the acquisition of shares at a price of $11.16, for a total value of $9,932. The purchase comes as the stock shows remarkable momentum, with a 72% return over the past year. According to InvestingPro analysis, the stock is currently trading near its Fair Value, while analyst targets suggest potential upside with a low target of $16 and a high target of $24.
Following this transaction, Trowbridge directly owns 256,629 shares of AngioDynamics INC. The company, with a market capitalization of $458.55 million, maintains a healthy balance sheet with a current ratio of 2.29 and operates with moderate debt levels. Get deeper insights into insider trading patterns and comprehensive financial analysis with InvestingPro’s detailed research reports.
In other recent news, AngioDynamics reported its fiscal first quarter 2026 earnings, surpassing both revenue and earnings per share (EPS) forecasts. The company achieved a revenue of $75.7 million, which exceeded the projected $72.7 million, and posted an EPS of -$0.10, beating the expected -$0.12. AngioDynamics’ Med Tech segment reported sales of $35.3 million, marking a 26.1% increase year-over-year, while the Med Device segment saw a 2.3% rise in sales to $40.4 million. H.C. Wainwright reiterated its Buy rating on AngioDynamics, maintaining a price target of $16.00. Meanwhile, Canaccord Genuity raised its price target for the company to $18.00 from $17.00, citing the strong performance of all three Med-Tech businesses and the company’s progress toward positive cash flow for fiscal year 2026. These developments reflect a positive outlook from analysts and highlight AngioDynamics’ robust financial performance in the recent quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.